How to Read Startup Milestones in a $300 Billion AI Market
Q1 2026 venture funding hit $300B, with four companies taking ~65% of it. How to read startup milestone announcements when the market is this concentrated.
Technology, AI & Digital Security
The latest technology, ai & digital security journalism from the publications of the VUGA Enterprises Network — refreshed around the clock. Every headline opens the full story at its source.
Page 7 of 7 · Updated 27 Oct 2026, 18:23 UTC
How Bioinformatics Pipelines Turn Raw Sequencing Data Into Usable Biology
What a bioinformatics pipeline does, why reproducibility dominates its design, and how Nextflow and nf-core standardize analysis across institutions.
How Orion and SLS Carry Astronauts Back to the Moon
How NASA's Orion capsule and Space Launch System work together for Artemis lunar missions, per NASA's own mission documentation.
Why Biotech Manufacturing Capacity Announcements Are Reshaping U.S. Drug Supply
S.
AMD's $5 Billion Anthropic Deal Shows How AI Partnerships Really Work
AMD will invest up to $5 billion in Anthropic and deploy 2 GW of MI450 GPUs (announced). What big AI partnership deals actually commit to, decoded.
Vertex Presents First Casgevy Data in Children Ages Five to 11 at ASH
Vertex presented the first Casgevy data in children ages 5-11 at ASH 2025; all evaluated children were free of vaso-occlusive crises for up to two years.
Johnson & Johnson Lifts 2026 Outlook After $25.3 Billion Second Quarter
4 billion, and raised full-year guidance.
FDA's Expedited IND Comment Window Nears Close After Gene Therapy Holds
FDA's comment window on the Expedited IND pilot closes July 22, 2026, after clinical holds hit REGENXBIO and Intellia gene therapy programs.
How Are AI-Enabled Medical Imaging Platforms Regulated by the FDA?
How FDA regulates AI-enabled imaging devices: the authorized device list, the 510(k) route most algorithms take, and what clearance does and does not mean.
What BioNTech's CEO Change Signals About Biotech Leadership Transitions
BioNTech's appointment of Sobi chief Guido Oelkers to succeed Ugur Sahin is a case study in how biotech boards execute leadership transitions.
The VUGA Enterprises Newsroom aggregates headlines and short excerpts from the newspapers and magazines of the VUGA Enterprises Network. Every headline links to the full story on the publishing site. Part of the VUGA Network.